30 September 2025
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")
Share Buyback Programme
Venture Life Group plc (AIM: VLG), a recognised leader in proactive healthy longevity, product innovation, development, and commercialisation within the global consumer healthcare sector, is pleased to announce that, following publication of the Company's interim results for the six months ended 30 June 2025, it will commence a share buyback programme (the "Programme") with immediate effect.
The Board believes that Venture Life's Ordinary Shares are undervalued relative to the Group's strong fundamentals and growth potential. By undertaking the Programme, the Company aims to enhance earnings per share and deliver greater value to its shareholders. The Programme will be funded from the Company's existing cash resources and is intended to reduce the share capital of the Company.
Pursuant to the terms of the Programme, the Company is seeking to repurchase up to 12,805,231 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares"), representing approximately 10 per cent. of the Company's existing issued share capital, in the market over the course of the period from the date of this announcement until 31 July 2026 (the "Expiry Date").
Ordinary Share repurchases will be made pursuant to the buyback authority granted at the Company's last Annual General Meeting. The maximum price which may be paid by the Company per Ordinary Share pursuant to the Programme shall not be more than 5 per cent above the average middle market quotations for an Ordinary Share (as derived from the London Stock Exchange AIM All-Share List) for the five business days immediately preceding the date on which such share is contracted to be purchased.
The Company has appointed Cavendish Capital Markets Limited ("Cavendish") to manage the Programme on its behalf on a broker-managed basis, with trading decisions taken independently of, and uninfluenced by, the Company. There is no certainty that the Programme will be completed and it may be paused at any time if deemed appropriate by Cavendish with respect to market conditions.
Venture Life intends to hold all of the repurchased Ordinary Shares as Treasury Shares.
The Company has determined that it will not rely on the safe harbour conditions for trading set out in Article 3(2) and Article 3(3) of the Commission Delegated Regulation (EU) 2016/1052 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) given the limited liquidity in the Ordinary Shares and limitations that the conditions would impose on the number of Ordinary Shares that can be purchased and, as such, the Company may (a) purchase Ordinary Shares at a price higher than the higher of the price of the last independent trade and the highest current independent bid for an Ordinary Share, and (b) purchase on any trading day materially in excess of 25 per cent of the average daily volume in the 20 trading days preceding the date on which the purchase is carried out.
As at 29 September 2025, the Company's total issued share capital consisted of 128,052,312 Ordinary Shares, with one voting right per share. As at this date the Group did not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Group is 128,052,312.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys/George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.